Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Fenethylline
Fenethylline — also known as Captagon — is a synthetic stimulant of the substituted amphetamine class. It links amphetamine to theophylline in a single molecule, designed to stimulate with less cardiovascular strain than amphetamine alone.[1] It boosts dopamine and norepinephrine while blocking adenosine receptors, producing both stimulant arousal and extended wakefulness.[2]
Fenethylline — also known as Captagon — is a synthetic stimulant of the substituted amphetamine class. It is a hybrid molecule linking amphetamine to theophylline, designed to produce stimulation with reduced cardiovascular strain.[1] Fenethylline drives monoamine release via the dopamine and norepinephrine transporters while blocking adenosine receptors, producing dual-pathway stimulation.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Synthesized in 1961 in Germany, fenethylline was sold as Captagon and prescribed for narcolepsy, hyperkinetic disorders, and depression.[1] The WHO banned it in 1986, ending legal manufacture globally — but clandestine producers adopted the name and flooded the Arabian Peninsula with counterfeit tablets.[3][4] Most tablets sold as "Captagon" today contain no genuine fenethylline; forensic analysis finds amphetamine, caffeine, and other adulterants instead.[4]
Subjective effects include stimulation, wakefulness, cognitive euphoria, appetite suppression, and heightened focus. The experience is smoother than pure amphetamine — a steady, even alertness with less jitteriness and a prolonged wakefulness from the theophylline component. Restlessness, insomnia, and anxiety are common unsought effects; paranoia and stimulant psychosis emerge at high or chronic doses.[5]
Fenethylline carries real dependence potential driven by its amphetamine metabolite; no human death has been directly attributed to the genuine compound.[6] Cardiovascular risks at abuse doses are serious: heart attack[7] and life-threatening rhythm changes[8] have been documented. Evidence is sparse — no controlled human study has been published, and most post-2000 data come from adulterated counterfeits rather than the original compound.[4]
History[edit]
Discovery
Fenethylline was synthesized in 1961 at Degussa AG in Germany, fusing amphetamine and theophylline into a single molecule designed to stimulate with less cardiovascular strain.[1] It reached the market the same year under the brand name Captagon as a 50 mg tablet, with additional brands including Fitton and Biocapton.[1]
Clinical use and prohibition
Fenethylline was prescribed across Europe for hyperkinetic disorders, narcolepsy, and depression.[6] Brief US availability ended after reports of hallucinations and psychosis; the US placed it on Schedule I in 1981.[4] In 1986, the WHO added it to the international drug convention, ending commercial manufacture globally.[3][4]
The counterfeit Captagon trade
Beginning in the early 2000s, clandestine labs — first in southeastern Europe, then predominantly in Syria — began mass-producing counterfeit Captagon tablets.[4] Forensic analyses consistently show these tablets contain amphetamine, caffeine, or other adulterants rather than genuine fenethylline.[4][9] By 2009, an estimated 700,000 counterfeit pills were consumed daily in Saudi Arabia alone.[10]
The name Captagon became a generic term for amphetamine-type stimulants across Arabic-language media, regardless of chemical content. It gained international notoriety through coverage linking it to Syrian civil war combatants and the 2015 Paris attacks,[6] cementing its reputation as a "war drug" — though this framing oversimplifies both the pharmacology and the economics of the trade.
Chemistry[edit]
Structure
Fenethylline belongs to two chemical families simultaneously: the substituted amphetamines and the xanthines.[11] Its structure fuses a theophylline (1,3-dimethylxanthine) unit to an amphetamine unit via a two-carbon bridge — making it the only xanthine–amphetamine conjugate to have reached clinical or illicit significance. Its closest structural relatives are amphetamine and theophylline.
Molecular properties
| Molecular formula | C₁₈H₂₃N₅O₂ |
| Molecular weight | 341.4 g/mol |
The molecule carries five nitrogen atoms distributed across the purine ring system and the bridging amine.[12]
Pharmacology[edit]
Mechanism of action
The body converts fenethylline into amphetamine and theophylline, but the intact parent molecule exerts its own effects beyond what its metabolites produce.[11] The amphetamine component drives dopamine and norepinephrine release; the theophylline component blocks adenosine receptors, extending wakefulness. These two pathways act together more powerfully than either metabolite alone.[2]
Cardiovascular effects
At therapeutic doses, fenethylline raises blood pressure less than equivalent amphetamine — the theophylline relaxes blood vessels, partially offsetting the stimulant's constricting effect.[1] At abuse doses, this offset collapses: heart attack[7] and dangerous heart rhythm changes[8] have been documented.
Pharmacokinetics
No controlled human pharmacokinetic study has been published.[13] The amphetamine metabolite accounts for 23–33% of the administered dose in urine over 48 hours; theophylline accounts for approximately 14%.[12] Standard drug panels detect the amphetamine metabolite but may miss fenethylline itself — it is listed among medications that can produce amphetamine-positive test results.[14]
Neuroscience[edit]
Where it acts
The amphetamine component floods the brain's reward circuit — from the ventral tegmental area to the nucleus accumbens — with dopamine, driving euphoria and the pull toward repeated use.[2] The theophylline component lifts sleep pressure by blocking adenosine receptors, extending wakefulness beyond physiological limits.
Why it matters
The intact fenethylline molecule produces a brain signature that neither amphetamine nor theophylline alone can replicate.[15] EEG recordings in rats showed a combined pattern of cortical activation and heightened arousal that neither metabolite could reproduce separately.
Counterfeit Captagon is meaningfully worse: unlike genuine fenethylline, it suppresses BDNF — a protein that supports learning and memory — in the prefrontal cortex.[9] This suggests illicit "Captagon" may carry worse long-term cognitive consequences than the original pharmaceutical.
Does the intact fenethylline molecule bind directly to any receptor, or does its unique activity arise from the timing and ratio of metabolite release? Does theophylline's dampening of dopamine sensitization translate to lower addiction rates in humans[2]? These questions may never be answerable — prohibition and the dominance of adulterated product make controlled human studies effectively impossible.
Subjective Effects[edit]
Fenethylline produces a sustained, functional alertness — smoother and more even than pure amphetamine. The dual pharmacology layers stimulant arousal over theophylline-extended wakefulness, creating an energy curve that builds gradually and holds longer. At common doses, the experience supports focus and sociability without the sharp cardiovascular edge of pure amphetamine.
Compared to Amphetamine, fenethylline shares the core character — wakefulness, appetite suppression, and cognitive euphoria — but delivers a smoother, more prolonged ride with a milder cardiovascular signature. Compared to methamphetamine, it is less potent and shorter-acting, with a distinct addiction profile shaped by its adenosine receptor antagonism.
Synthesized in 1961 at Degussa AG in Germany, fenethylline entered the market as a 50 mg tablet under the trade name Captagon.[1] It was prescribed across Europe for hyperkinetic disorders, narcolepsy, and depression until international prohibition in 1986.[3] Today, billions of tablets branded "Captagon" circulate across the Arabian Peninsula and conflict zones of the Levant, though most contain no genuine fenethylline.[4]
Subjective effects include stimulation, wakefulness, cognitive euphoria, and appetite suppression. The experience is described as a sustained, smooth alertness — less jittery than pure amphetamine at comparable doses, with pronounced extension of wakefulness from the xanthine component. Restlessness, insomnia, and anxiety are characteristic unsought effects, with paranoia and stimulant psychosis emerging at high or chronic doses.[5]
Fenethylline carries significant abuse liability driven by its amphetamine metabolite's dopaminergic reinforcement; no human fatalities have been directly attributed to genuine fenethylline.[6] Cardiovascular toxicity — including acute myocardial infarction[7] and dangerous cardiac rhythm changes[8] — is documented at abuse doses, and chronic use produces stimulant psychosis with distinctive delusions of jealousy.[5] No controlled human pharmacokinetic study has been published, and post-prohibition clinical data are confounded by counterfeit formulations containing unknown adulterants.[4]
History[edit]
Discovery
Fenethylline was synthesized in 1961 by chemists at Degussa AG in Germany, who coupled amphetamine with theophylline to create a single molecule intended to deliver stimulation with less cardiovascular stress than amphetamine alone.[1] The compound reached the West German market the same year as a 50 mg tablet under the trade name Captagon, with additional brands including Fitton and Biocapton.[1] By 1964, West German authorities had imposed strict prescription requirements.[1]
Clinical use and prohibition
During its quarter-century of legitimate availability, fenethylline was prescribed for hyperkinetic disorders in children, narcolepsy, and depression across Europe.[6] It briefly reached the United States before withdrawal due to post-marketing reports of hallucinations and psychosis.[6] The US placed fenethylline on Schedule I in 1981,[4] and in 1986 the WHO added it to the Convention on Psychotropic Substances, triggering global prohibition and the end of commercial manufacture.[3][4]
The counterfeit Captagon trade
The trade name outlived its molecule. Beginning in the early 2000s, clandestine laboratories — first in southeastern Europe, then predominantly in Syria — began mass-producing tablets stamped with the Captagon logo.[4] By 2009, an estimated 700,000 counterfeit pills were consumed daily in Saudi Arabia alone,[9] and seizures escalated through the 2010s, with Dubai customs intercepting over 29 million pills in a single 2014 operation.[4] The substance became entangled with the Syrian civil war, earning the label "chemical courage" among combatants.[6][4] Forensic analyses consistently show that modern "Captagon" tablets contain amphetamine, caffeine, or other adulterants rather than genuine fenethylline — rendering post-2000 clinical data unreliable as evidence about the original compound.[4][10]
The name Captagon outlived its molecule to become one of the most recognized drug brand names in the Middle East. In Arabic-language media, "Captagon" functions as a generic term for amphetamine-type stimulants regardless of actual chemical content. The substance gained international notoriety when media linked it to combatants in the Syrian civil war and referenced it in coverage of the 2015 Paris attacks,[6] cementing its reputation as a "war drug" — though this framing oversimplifies both the pharmacology and the economics of the trade.
Chemistry[edit]
Structure
Fenethylline belongs simultaneously to two chemical families: the substituted amphetamines and the xanthines. Its molecular architecture consists of a theophylline (1,3-dimethylxanthine) moiety linked via a two-carbon ethylamine bridge to an amphetamine moiety.[11] This hybrid design makes fenethylline structurally unique among stimulants — it is neither a simple amphetamine derivative nor a simple xanthine derivative, but a bifunctional molecule whose pharmacology cannot be reduced to either parent scaffold.
No other xanthine–amphetamine conjugate has achieved clinical or illicit significance, making fenethylline the sole representative of its structural subclass. Its closest structural relatives are amphetamine itself and theophylline.
Molecular properties
| Molecular formula | C₁₈H₂₃N₅O₂ |
| Molecular weight | 341.4 g/mol |
The molecule contains five nitrogen atoms distributed across the purine ring system and the bridging amine. The theophylline domain carries methyl groups at N-1 and N-3, while the N-7 position connects through the ethylamine bridge to the alpha-carbon of the amphetamine phenethylamine skeleton.[12]
Stereochemistry
Fenethylline has one stereocenter at the alpha-carbon of its amphetamine moiety. The pharmaceutical preparation was marketed as a racemic mixture. No published data distinguish the pharmacological activity of fenethylline's individual enantiomers, though for amphetamine itself the (S)-(+) isomer is the more potent central stimulant.citation needed
Physical properties
The hydrochloride salt — the form used in pharmaceutical tablets and clandestine manufacture — is a white to off-white crystalline powder that melts at 227–229 °C.[1] It dissolves readily in water and ethanol but has limited solubility in nonpolar solvents.[1]
Pharmacology[edit]
Mechanism of action
Fenethylline is more than the sum of its metabolites. While the body cleaves it into amphetamine and theophylline, the intact parent molecule exerts its own pharmacological activity — effects track more closely with parent-compound blood levels than with metabolite concentrations.[11]
The amphetamine component, released during metabolism, forces dopamine and norepinephrine out of nerve terminals by reversing their transporters (DAT and NET). It also activates TAAR1 (TAAR1), a mechanism identified as the primary driver of fenethylline's addictive potential and its propensity to produce irritability and aggression.[2]
The theophylline component blocks adenosine A₁ and A₂A receptors. Adenosine normally accumulates during wakefulness and promotes sleep; blocking its receptors extends alertness and produces the characteristic sustained wakefulness. A₂A blockade in the striatum also dampens behavioral sensitization caused by the amphetamine component, which may partly explain why fenethylline carries somewhat lower abuse potential than pure amphetamine.[2]
These two arms interact synergistically: concurrent TAAR1 activation and A₂A blockade produces faster and more potent effects than either metabolite alone.[2] A metabolic feedback loop amplifies the interaction — the amphetamine metabolite inhibits CYP2D6, slowing theophylline clearance and extending its duration of action.[2]
Cardiovascular effects
At therapeutic doses, fenethylline raises blood pressure less than equivalent doses of amphetamine, an effect attributed to theophylline's blood-vessel-relaxing properties.[1] At recreational and abuse doses, this protective offset is overwhelmed: blood-vessel constriction and rhythm disruption dominate, as documented in cases of Brugada phenocopy[8] and acute myocardial infarction.[7]
Pharmacokinetics
No controlled human pharmacokinetic study has been published. The limited available data come from metabolite analysis in three male volunteers.[13]
The body cleaves fenethylline at two sites on the ethylamine bridge. The dominant pathway in humans produces amphetamine, accounting for 23–33% of the administered dose in urine over 48 hours. Theophylline accounts for approximately 13.7% of the dose.[12] Only a fraction of the amphetamine theoretically available in the molecule is actually released, consistent with the parent compound — not its metabolites — driving the acute effects.[11]
Detection
Standard drug screening panels detect the amphetamine metabolite but may not identify fenethylline itself without targeted laboratory analysis.[14] In hair samples, fenethylline concentrations run 1.2–2.7 times higher than amphetamine, but fenethylline clears from urine faster than its amphetamine metabolite.[12] Fenethylline is listed among medications capable of producing amphetamine-positive drug test results.[14]
Neuroscience[edit]
Where it acts
Fenethylline engages two neurochemical systems simultaneously. The amphetamine component amplifies dopamine signaling in the brain's mesolimbic pathway — the circuit running from the ventral tegmental area to the nucleus accumbens — driving euphoria, motivation, and the potential for compulsive redosing.[2] In the prefrontal cortex, released norepinephrine and dopamine sharpen attention and working memory at low doses but produce cognitive rigidity and decision impairment when concentrations climb too high.
The theophylline component lifts the brain's sleep pressure by blocking adenosine receptors in the basal forebrain, extending wakefulness beyond physiological limits. In the striatum, adenosine A₂A receptors form functional partnerships with dopamine D₂ receptors; blocking A₂A reduces the reinforcing power of dopamine release, potentially slowing the progression from casual use to compulsion.[2]
Why it matters
Fenethylline produces a distinct neurophysiological fingerprint. Quantitative EEG in rats showed reduced alpha-band power (a theophylline signature, reflecting cortical activation) combined with increased beta-1 power (an amphetamine signature, reflecting heightened arousal).[15] Neither metabolite alone reproduced this pattern, providing direct evidence that the intact molecule has neurological effects beyond what its parts deliver separately.
Animal comparisons reveal another important distinction: genuine fenethylline at high doses produces overheating and hyperactivity, but counterfeit captagon formulations cause significantly greater effects and — unlike genuine fenethylline — reduce BDNF expression in the prefrontal cortex.[10] BDNF supports learning, memory, and brain adaptability; its suppression suggests the illicit product may carry worse long-term cognitive consequences than the original pharmaceutical.
Does the intact fenethylline molecule bind directly to any receptor, or does its unique activity arise purely from the timing and ratio of metabolite release? Does theophylline's dampening of dopamine sensitization translate to lower addiction rates in humans, or is this effect limited to animal models[2]? What are the long-term cognitive consequences of genuine fenethylline use at human-relevant doses — a question that may never be answerable given the compound's prohibition and the dominance of adulterated product?
Subjective Effects[edit]
Fenethylline produces a stimulant experience shaped by its dual pharmacology — amphetamine-driven catecholaminergic arousal layered with theophylline-mediated wakefulness extension. At common doses, the result is a sustained, functional alertness described as smoother than pure amphetamine, with less cardiovascular tension and a more even energy curve. Set and setting modulate the experience substantially: acute use supports focus and sociability, while chronic high-dose patterns shift the profile toward paranoia, cognitive rigidity, and psychosis.
Relative to Amphetamine, fenethylline shares the core character of wakefulness, appetite suppression, and cognitive euphoria, but the xanthine component adds a distinctive prolongation of arousal and a mildly reduced cardiovascular edge at equivalent doses. Compared to methamphetamine, fenethylline is less potent and shorter-acting, with a distinct — though incompletely characterized — abuse liability profile shaped by its adenosine receptor antagonism.
Effect Grid
Clear stimulation with sustained wakefulness, cognitive euphoria, and enhanced focus. Thought acceleration and motivation enhancement are noticeable. Appetite suppression is prominent. Sociability may be enhanced. The 50 mg pharmaceutical tablet — the standard clinical unit — falls squarely in this range.
Physical effects include moderate heart rate increase, dry mouth, possible muscle tension, and mild restlessness. The theophylline component provides a vasodilatory counterbalance that keeps blood pressure elevation modest relative to equivalent amphetamine doses.
Insomnia is likely if taken within 6-8 hours of intended sleep. Duration of primary effects is approximately 3-4 hours, with residual wakefulness extending beyond.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Heart rate perception changes · Insomnia · Physical fatigue · Pupil dilation · Restlessness · Dehydration sensation · Excessive sweating · Muscle tension · Body high · Bruxism · Respiratory stimulation · Dizziness · Headache · Increased urination · Nausea · Sexual arousal enhancement · Tactile euphoria · Trembling · Diarrhea · Vomiting
Restlessness · Dehydration sensation · Excessive sweating · Muscle tension · Body high · Bruxism · Respiratory stimulation · Dizziness · Headache · Increased urination · Nausea · Sexual arousal enhancement · Tactile euphoria · Trembling · Diarrhea · Vomiting
Motivation enhancement · Analysis enhancement · Information processing enhancement · Language enhancement · Thought organization · Cognitive flexibility · Pattern recognition enhancement · Creativity enhancement · Memory enhancement
Thought organization · Cognitive flexibility · Pattern recognition enhancement · Creativity enhancement · Memory enhancement
Anhedonia · Dysphoria · Emotional lability · Mania
Sociability enhancement · Social connection · Flow state
Timeline
Gradual absorption of the hydrochloride salt. Minimal perceptible effects — perhaps a faint awareness of emerging alertness as the parent compound reaches initial plasma levels.
Stimulation becomes clearly perceptible. Alertness, mild mood elevation, and the first signs of appetite suppression emerge as fenethylline reaches effective plasma concentrations.
Full stimulant effect — sustained wakefulness, cognitive euphoria, appetite suppression, enhanced focus, and cardiovascular activation. The dual amphetamine-theophylline pharmacology is maximally expressed.
Gradual decline in stimulation and euphoria. Residual wakefulness and appetite suppression persist. Irritability or restlessness may emerge as the rewarding effects fade while sympathomimetic tone remains.
Residual insomnia, possible irritability and fatigue as the amphetamine metabolite clears (t½ 10-13 hours). Theophylline clearance may be prolonged by CYP2D6 inhibition.
⚠ Avoid driving or operating machinery for at least 6 hours after dosing — residual impairment from sleep deprivation and comedown fatigue may persist beyond subjective stimulant effects.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 14 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · other amphetamine-type stimulants
Toxicity
No lethal dose has been established for fenethylline in any species, and no human death has been directly attributed to genuine fenethylline.[6] This reflects the scarcity of post-prohibition studies on the genuine molecule — not evidence of safety.
Heart and circulation
Fenethylline poses serious cardiovascular risks at abuse doses. A 23-year-old suffered a heart attack after captagon use, caused by coronary blood vessel spasm.[7] Two cases of reversible Brugada-pattern rhythm changes — a condition predisposing to sudden cardiac death — have been documented.[8]
Combining captagon with azithromycin (a common antibiotic) produced synergistic heart damage in rat models, including significant QT prolongation and markers of heart cell death.[16] This combination should be considered dangerous.
Neurotoxicity
Counterfeit Captagon is more neurotoxic than genuine fenethylline. It suppresses BDNF — a protein essential for learning and memory — in the prefrontal cortex, an effect not seen with the genuine compound.[9]
Psychological risks
Stimulant psychosis is the most documented psychiatric complication, and hallucinations drove fenethylline's withdrawal from the US market.[6] In a Saudi Arabian inpatient study, 25.7% of captagon users developed delusions of infidelity (morbid jealousy), associated with a 53.8% divorce rate in that group.[5] People with a personal or family history of psychotic disorders carry substantially elevated risk.[2]
Tolerance and dependence
Fenethylline produces real dependence, driven by the same dopaminergic mechanisms as amphetamine.[2] Three-quarters of drug treatment admissions in Saudi Arabia involve captagon dependence.[17]
Withdrawal symptoms — fatigue, depression, craving, and sleep disruption — are consistent with amphetamine-class discontinuation.[18] No formal withdrawal protocol exists for fenethylline.[3]
Drug Interactions
The amphetamine metabolite releases serotonin, so combining fenethylline with serotonin-raising drugs — MAOIs, SSRIs, SNRIs, tramadol — risks serotonin syndrome: dangerous overheating, muscle rigidity, and cardiovascular collapse. The MAOI combination is catastrophic.safety citation needed Combining with QT-prolonging drugs — antibiotics like azithromycin, antipsychotics, or heart medications — carries synergistic heart toxicity risk.[16]
The amphetamine metabolite inhibits CYP2D6, slowing the breakdown of many other drugs.[2] Drugs with narrow safety margins that rely on CYP2D6 — certain antidepressants, codeine, tramadol, and metoprolol — may reach toxic levels. Combining with other stimulants adds cardiovascular stress and raises seizure and psychosis risk.
Contraindications
9 knownAbsolute
- MAOI use (current or within 14 days): risk of catastrophic blood pressure crisis and serotonin syndromesafety citation needed
- Known Brugada syndrome: fenethylline can induce Brugada-pattern rhythm changes even in those without the condition;[8] established Brugada syndrome substantially elevates the risk of fatal rhythm disturbance
- Recent heart attack or unstable chest pain: blood vessel spasm risk documented in case report[7]
Relative
- Heart rhythm abnormalities or prolonged QT: arrhythmia risk, particularly with QT-prolonging medications[16]
- History of psychotic disorders or family history of schizophrenia: dose-dependent psychosis risk[5]
- Coronary artery disease: blood vessel spasm and accelerated artery damage[19]
- Liver impairment affecting drug metabolism: altered metabolite ratios and unpredictable effects[20]
- Concurrent use of CYP2D6-metabolized drugs with narrow safety margins: risk of toxic drug levels[2]
- Pregnancy and lactation: no fenethylline-specific safety data; amphetamine-class compounds cross the placenta and enter breast milksafety citation needed
Harm Reduction[edit]
Forms & Identification
Almost no tablet sold as "Captagon" today contains genuine fenethylline. Forensic analyses consistently find amphetamine, caffeine, and rotating adulterants including methamphetamine, procaine, and chloroquine.[4][9]
Reagent tests and dosing expectations calibrated to pharmaceutical fenethylline are unreliable for street Captagon. Quantitative laboratory analysis through a drug checking service is the only way to confirm actual contents and concentrations.
Guidelines
- Test every batch. Standard amphetamine reagent kits confirm the presence of an amphetamine-type substance but cannot distinguish genuine fenethylline from amphetamine or methamphetamine. Send a sample to a drug checking service for quantitative analysis if available.
- Start low. Street Captagon potency varies unpredictably between batches and even between tablets from the same batch.
- Do not redose within the first two hours. Onset is slow (90–120 minutes), and premature redosing is a common path to overdose-range exposure.
- Eat beforehand. Stimulants suppress appetite; starting without food increases risk of dehydration, blood sugar drops, and physical exhaustion.
- Set a hard stop. Decide in advance when the session ends. Stimulant-driven wakefulness makes it easy to extend use across days, which sharply increases psychosis and cardiovascular risk.
- Stay hydrated but do not overdrink. Sip water steadily; avoid alcohol, which masks stimulant warning signs.
Set & Setting
Fenethylline's stimulant effects are powerfully shaped by environment. A calm, familiar setting with trusted people reduces the risk of paranoia and anxious fixation that can escalate under stimulant influence. Avoid high-stress situations, confrontational social settings, or environments demanding sustained physical exertion in heat — stimulant-driven overheating is a medical emergency.
Mental state matters equally. Pre-existing anxiety, sleep deprivation, or emotional distress amplify the negative psychological trajectory of stimulant use. Open-ended stimulant use with no defined endpoint is the pattern most associated with dose escalation and psychosis.
Aftercare & integration. The stimulant comedown brings fatigue, low mood, and strong cravings. Sleep is the single most effective recovery intervention — prioritize it even if it takes time to arrive naturally. Eat calorie-dense, nutritious food as soon as appetite returns.
Allow 48–72 hours of recovery before making important decisions or assessing mood. Stimulant withdrawal depression is temporary but can feel absolute. If low mood persists beyond a week, or if paranoid thoughts linger after the drug has cleared, seek professional evaluation.
Recovery & Support
Fenethylline dependence is driven by the same dopaminergic mechanisms as amphetamine dependence, and the same treatment approaches apply. No fenethylline-specific discontinuation protocol has been published.[3]
Cognitive behavioral therapy is the best-supported intervention for amphetamine-type stimulant use disorders. Peer support groups — including SMART Recovery and 12-step programs adapted for stimulant use — provide structured accountability. If daily use has become established, medical supervision during discontinuation is advisable.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, seizure, loss of consciousness, or body temperature hot enough to feel through clothing are medical emergencies — not uncomfortable side effects. Severe paranoia with loss of contact with reality, or aggression directed at self or others, also requires immediate intervention.
Immediate steps:
- 1. Call emergency services.
- 2. Move the person to a cool, quiet environment if possible.
- 3. If unconscious but breathing, place in the recovery position.
- 4. Do not restrain unless there is immediate danger of self-harm or harm to others — restraint can worsen overheating.
- 5. Do not induce vomiting.
What to tell the dispatcher: Name the substance (or "Captagon / amphetamine-type stimulant"), the amount taken if known, when it was taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No specific reversal agent exists for amphetamine-type stimulant toxicity. Hospital treatment focuses on cooling, sedation (typically benzodiazepines), and cardiac monitoring.
Legal Status[edit]
Fenethylline is prohibited in virtually every country party to the 1971 Convention on Psychotropic Substances, which added it in 1986.[3][4]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Placed on Schedule I in 1981; no accepted medical use, high abuse potential[4][12] |
| United Kingdom | Class C (Misuse of Drugs Act 1971) | Added by the 1986 Modification Order[21] |
| Canada | Schedule III (Controlled Drugs and Substances Act) | Controlled substance[12] |
| International | Convention on Psychotropic Substances (1971) | Added 1986 by WHO recommendation; binding on all signatory states[3] |
| Australia | Presumed prohibited | Specific TGA schedule not confirmed; expected controlled as an amphetamine-type substancecitation needed |
| Saudi Arabia, Jordan, Syria | Illegal | Enforcement challenged by scale of counterfeit captagon production and consumption[17][22] |
Anti-doping status
Fenethylline metabolizes to amphetamine, a WADA-prohibited stimulant. Fenethylline itself is explicitly listed on the WADA Prohibited List, and use results in a positive doping test for amphetamines.[14]
Legal status changes frequently and varies by jurisdiction. This information is not legal advice. Verify the current law in the relevant jurisdiction before making any decisions.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 14 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · other amphetamine-type stimulants
Toxicity
No lethal dose has been established for fenethylline in any species, and no human deaths have been directly attributed to genuine fenethylline.[6] This does not indicate safety — it reflects the small number of post-prohibition studies examining the genuine molecule rather than counterfeit captagon.
Heart and circulation
Fenethylline poses serious cardiovascular risks at abuse doses. A 23-year-old male suffered a heart attack after captagon ingestion, attributed to coronary blood vessel spasm.[7] Two cases of reversible Brugada-pattern heart rhythm abnormality — a condition predisposing to sudden cardiac death — have been documented during fenethylline abuse, both resolving after discontinuation.[8]
Rat models show elevated cardiac stress markers and prolonged QT intervals.[16] A systematic review of amphetamine-type stimulants identifies coronary blood vessel spasm, accelerated artery damage, platelet activation, and direct heart muscle toxicity as mechanisms of cardiovascular harm.[17]
Combining captagon with azithromycin (a common antibiotic) produced synergistic heart damage in rat models, including significant QT prolongation and markers of heart cell death.[16] This combination should be considered dangerous.
Neurotoxicity
Genuine fenethylline at high doses (50–100 mg/kg in rats) causes dose-dependent overheating and hyperactivity. Counterfeit captagon formulations produce significantly greater effects at comparable doses and — unlike genuine fenethylline — suppress BDNF, a protein essential for learning and brain adaptability.[10] The neurotoxicity of illicit "Captagon" exceeds that of the original pharmaceutical compound.
Psychological risks
Stimulant psychosis is the most thoroughly documented psychiatric complication. In a study of 101 male inpatients in Saudi Arabia, regular captagon doses ranged from 1–15 tablets daily, with maximum doses reaching 25 tablets.[5] A distinctive feature was delusions of infidelity (morbid jealousy) in 25.7% of cases, associated with a 53.8% divorce rate in that subgroup.[5]
Hallucinations and visual distortions were the reason for fenethylline's withdrawal from the US market.[6] Paranoia, aggression, and irritability are consistent with excessive dopamine release driven by TAAR1 activation.[2] Persons with personal or family history of psychotic disorders are at substantially elevated risk. Combat and conflict use — characterized by high doses sustained over days — represents an extreme exposure pattern with maximal psychiatric risk.[4]
Tolerance and dependence
Fenethylline's classification under Schedule I and international prohibition were driven partly by documented addictive potential.[3] The reinforcement mechanism is primarily dopaminergic: the amphetamine metabolite drives reward signaling through TAAR1 activation and transporter reversal.[2] Three-quarters of drug treatment admissions in Saudi Arabia involve amphetamine addiction, almost exclusively in the captagon form.[18]
No formal withdrawal characterization exists for fenethylline. Reports from captagon users describe symptoms consistent with amphetamine-class discontinuation: crash fatigue, depression, craving, and sleep disturbance.[19] Developing standardized withdrawal protocols has been identified as a significant knowledge gap.[3]
No controlled tolerance data exist. The dual pharmacology adds complexity: while standard amphetamine-type tolerance would be expected, the amphetamine metabolite's inhibition of CYP2D6 slows theophylline clearance, potentially maintaining wakefulness-promoting effects even as dopaminergic tolerance develops.[2] Cross-tolerance with other amphetamine-type stimulants is expected but unconfirmed.
Drug Interactions
The amphetamine metabolite releases serotonin, making combination with serotonergic drugs — including MAOIs, SSRIs, SNRIs, and tramadol — a risk for serotonin syndrome, a life-threatening condition involving dangerous overheating, muscle rigidity, and cardiovascular instability. The MAOI interaction is classified as catastrophic based on amphetamine-class pharmacology.safety citation needed
Combination with QT-prolonging drugs — including macrolide antibiotics (particularly azithromycin), antipsychotics, and certain heart rhythm medications — poses synergistic heart toxicity risk. The captagon–azithromycin combination specifically has been shown to produce synergistic QT prolongation in rat models.[16]
The amphetamine metabolite inhibits CYP2D6.[2] Co-administration with drugs metabolized by this enzyme that have narrow safety margins — including certain antidepressants, antipsychotics, opioids (codeine, tramadol), and heart medications (metoprolol) — may elevate those drugs to toxic levels.
Co-use with other stimulants (cocaine, caffeine, methamphetamine) produces additive cardiovascular stress and increased seizure and psychosis risk.
Contraindications
9 knownAbsolute
- MAOI use (current or within 14 days): risk of catastrophic blood pressure crisis and serotonin syndromesafety citation needed
- Known Brugada syndrome: fenethylline can induce Brugada-pattern rhythm changes even in people without the condition;[8] in those with established Brugada syndrome, the risk of fatal rhythm disturbance is substantially elevated
- Recent heart attack or unstable chest pain: blood vessel spasm risk documented in case report[7]
Relative
- Heart rhythm abnormalities or prolonged QT: arrhythmia risk, particularly with QT-prolonging medications[16]
- History of psychotic disorders or family history of schizophrenia: dose-dependent psychosis risk[5]
- Coronary artery disease: blood vessel spasm and accelerated artery damage from amphetamine-class mechanisms[17]
- Liver impairment affecting drug metabolism: altered metabolite ratios and unpredictable effects[20]
- Concurrent use of CYP2D6-metabolized drugs with narrow safety margins: risk of toxic drug levels[2]
- Pregnancy and lactation: no fenethylline-specific safety data exist; amphetamine-class compounds cross the placenta and enter breast milksafety citation needed
Harm Reduction[edit]
Forms & Identification
The defining challenge with fenethylline is that almost no tablet sold as "Captagon" today contains genuine fenethylline. Forensic analyses consistently find amphetamine, caffeine, and a rotating cast of adulterants including methamphetamine, procaine, and chloroquine.[4][10] This means reagent testing and dosing expectations calibrated to pharmaceutical fenethylline are unreliable for street-market Captagon. Quantitative laboratory analysis through a drug checking service is the only way to confirm actual contents and concentrations.
Guidelines
- Test every batch. Standard amphetamine reagent kits confirm the presence of an amphetamine-type substance but cannot distinguish genuine fenethylline from amphetamine or methamphetamine. If available, send a sample to a drug checking service for quantitative analysis.
- Start low. The unknown composition of street Captagon means potency varies unpredictably between batches and even between tablets from the same batch.
- Do not redose within the first two hours. Onset is slow (90–120 minutes), and premature redosing is a common path to overdose-range exposure.
- Eat beforehand. Stimulants suppress appetite; entering a session without food increases risk of dehydration, blood sugar drops, and physical exhaustion.
- Set a hard stop. Decide in advance when the session ends. Stimulant-driven wakefulness makes it easy to extend use across days, which sharply increases psychosis and cardiovascular risk.
- Stay hydrated but do not overdrink. Sip water steadily; avoid alcohol, which masks stimulant warning signs.
Set & Setting
Fenethylline's stimulant effects are powerfully shaped by environment. A calm, familiar setting with trusted companions reduces the risk of paranoia and anxious fixation that can escalate under stimulant influence. Avoid high-stress environments, confrontational social situations, or settings that demand sustained physical exertion in heat — stimulant-driven overheating is a medical emergency.
Mental state matters equally. Pre-existing anxiety, sleep deprivation, or emotional distress amplify the negative psychological trajectory of stimulant use. If the purpose is sustained work or study, ensure the task is defined and the environment controlled; open-ended stimulant use with no endpoint is the pattern most associated with dose escalation and psychosis.
Aftercare & integration. The stimulant comedown is characterized by fatigue, low mood, and strong cravings. Sleep is the single most effective recovery intervention — prioritize it even if it takes time to arrive naturally. Eat calorie-dense, nutritious food as soon as appetite returns; the body has been running on reserves.
Allow 48–72 hours of recovery before making important decisions or assessing mood. Stimulant withdrawal depression is temporary but can feel absolute. If low mood persists beyond a week, or if paranoid thoughts linger after the drug has cleared, seek professional evaluation.
Recovery & Support
Fenethylline dependence is driven by the same dopaminergic mechanisms as amphetamine dependence, and the same treatment approaches apply. No fenethylline-specific discontinuation protocol has been published.[3]
Cognitive behavioral therapy is the best-supported intervention for amphetamine-type stimulant use disorders. Peer support groups — including SMART Recovery and 12-step programs adapted for stimulant use — provide structured accountability. If daily use has become established, medical supervision during discontinuation is advisable to monitor mood, sleep disruption, and cardiovascular recovery.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, seizure, loss of consciousness, or body temperature hot enough to feel through clothing are medical emergencies — not uncomfortable side effects. Severe paranoia with loss of contact with reality, or aggression directed at self or others, also requires immediate intervention.
Immediate steps:
- 1. Call emergency services.
- 2. Move the person to a cool, quiet environment if possible.
- 3. If unconscious but breathing, place in the recovery position.
- 4. Do not restrain unless there is immediate danger of self-harm or harm to others — restraint can worsen overheating.
- 5. Do not induce vomiting.
What to tell the dispatcher: Name the substance (or "Captagon / amphetamine-type stimulant"), the amount taken if known, when it was taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No specific reversal agent exists for amphetamine-type stimulant toxicity. Hospital treatment focuses on cooling, sedation (typically benzodiazepines), and cardiac monitoring.
Legal Status[edit]
Fenethylline is prohibited or controlled in virtually every jurisdiction party to the 1971 Convention on Psychotropic Substances. The WHO added fenethylline to the Convention in 1986, citing addictive and hallucinogenic properties.[3][4] Commercial pharmaceutical production ceased globally by the end of that year. Despite universal prohibition, enforcement is challenged by the scale of clandestine production — principally in Syria — and consumption across the Arabian Peninsula.[18]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Placed on Schedule I in 1981; no accepted medical use, high abuse potential[4][12] |
| United Kingdom | Class C (Misuse of Drugs Act 1971) | Added by the 1986 Modification Order[21] |
| Canada | Schedule III (Controlled Drugs and Substances Act) | Controlled substance[12] |
| International | Convention on Psychotropic Substances (1971) | Added 1986 by WHO recommendation; binding on all signatory states[3] |
| Australia | Presumed prohibited | Specific TGA schedule not confirmed; expected controlled as an amphetamine-type substancecitation needed |
| Saudi Arabia, Jordan, Syria | Illegal | Enforcement challenged by scale of counterfeit captagon production and consumption[18][22] |
Anti-doping status
Fenethylline metabolizes to amphetamine, a WADA S6 prohibited stimulant. Fenethylline itself is explicitly listed under WADA's Prohibited List as an amphetamine-type stimulant. Use results in a positive doping test for amphetamines.[14]
Frequently asked questions
What is Fenethylline?
Fenethylline is a synthetic stimulant of the substituted amphetamine and xanthine classes, marketed from 1961 as Captagon. It acts as a theophylline-amphetamine conjugate releasing both metabolites while exerting intrinsic parent-molecule activity at catecholaminergic and adenosinergic targets.
How long does Fenethylline last?
Total duration by route of administration — Oral: 3 – 4 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Fenethylline?
Psychedex publishes a dosage table for Fenethylline on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Fenethylline?
The highest-severity documented interactions for Fenethylline: MAOIs (Lethal), 5-HTP, Tryptophan (Dangerous), Alpha-2 adrenergic receptor antagonist (Dangerous), Amphetamines (Dangerous), Anticholinergics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Fenethylline addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Fenethylline: tolerance builds moderate; full reset takes 14 days; cross-tolerance develops with amphetamine, methamphetamine, other amphetamine-type stimulants. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3]
- [4]
- [5] ^abcShalaby AS, Badr Nassar OM, Bahanan AO, Alshehri MH, Nasr Abou Elzahab NF (2023) Captagone & Morbid Jealousy — Psychopharmacology Bulletin PMID:36873918
- [6]
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]